gbt
presents
data
annual
scientific
conference
sickle
cell
thalassemia
effectiveness
data
voxelotor
treatment
sickle
cell
disease
featured
oral
presentation
south
san
francisco
globe
newswire
global
blood
therapeutics
gbt
nasdaq
gbt
today
announced
participation
annual
scientific
conference
sickle
cell
thalassemia
ascat
eha
european
sickle
cell
conference
taking
place
online
two
abstracts
accepted
presentation
including
effectiveness
data
voxelotor
tablets
treatment
sickle
cell
disease
scd
gbt
focused
addressing
sickle
cell
disease
root
cause
seek
modify
course
disease
ultimately
mitigate
serious
complications
often
lead
damage
early
death
said
ted
love
president
ceo
gbt
pleased
ascat
sharing
effectiveness
data
demonstrating
benefits
treatment
sickle
cell
patients
oxbryta
consistent
results
phase
hope
two
abstracts
presented
conference
provide
greater
insight
safety
efficacy
oxbryta
retrospective
chart
review
study
assess
effectiveness
voxelotor
based
data
first
several
months
fda
approval
sample
charts
patients
scd
voxelotor
increased
hemoglobin
g
dl
average
decreased
hemolysis
markers
degree
consistent
randomized
controlled
hope
trial
results
evidence
also
suggests
voxelotor
treatment
associated
improvement
important
symptoms
scd
pain
fatigue
aspects
quality
life
case
report
patient
scd
treated
voxelotor
presenting
significant
drop
hemoglobin
responsive
transfusion
red
blood
cells
association
hospitalization
case
patient
hemoglobin
overall
clinical
status
improved
rapidly
voxelotor
treatment
thereby
avoiding
exchange
transfusion
sparing
red
blood
cell
units
decreasing
exposure
health
care
providers
important
considerations
era
pandemic
limited
blood
supply
details
ascat
presentations
follows
wednesday
abstract
session
new
therapies
effectiveness
voxelotor
treatment
sickle
cell
disease
chart
review
study
presenter
kenneth
bridges
gbt
time
gmt
virtual
presentation
poster
room
sickle
cell
anemia
use
voxelotor
avoid
transfusion
presenter
william
ershler
inova
schar
cancer
institute
part
presence
ascat
gbt
host
educational
online
symposium
getting
root
cause
understanding
devastating
impact
scd
patients
monday
gmt
symposium
include
presentations
caterina
minniti
professor
clinical
medicine
pediatrics
einstein
college
medicine
director
sickle
cell
center
adults
montefiore
medical
center
bart
biemond
professor
internal
medicine
hematologist
faculty
medicine
university
amsterdam
information
symposium
available
registered
attendees
ascat
meeting
found
conference
program
coinciding
ascat
today
gbt
released
comprehensive
report
overview
sickle
cell
disease
environment
select
european
countries
order
help
raise
awareness
scd
europe
report
based
research
conducted
five
european
countries
explores
burden
disease
patients
families
health
care
systems
addition
report
examines
existing
public
policy
efforts
address
alleviate
challenges
faced
living
scd
scd
one
prevalent
genetic
rare
diseases
europe
despite
clinical
understanding
scd
estimated
life
expectancy
affected
disease
significantly
lower
european
average
indicating
urgent
need
improve
quality
care
patients
sickle
cell
disease
sickle
cell
disease
scd
affects
estimated
people
united
estimated
people
millions
people
throughout
world
particularly
among
whose
ancestors
also
affects
people
hispanic
south
asian
southern
european
middle
eastern
scd
lifelong
inherited
rare
blood
disorder
impacts
hemoglobin
protein
carried
red
blood
cells
delivers
oxygen
tissues
organs
throughout
due
genetic
mutation
individuals
scd
form
abnormal
hemoglobin
known
sickle
hemoglobin
process
called
hemoglobin
polymerization
red
blood
cells
become
sickled
deoxygenated
sickling
process
causes
hemolytic
anemia
low
hemoglobin
due
red
blood
cell
destruction
blockages
capillaries
small
blood
vessels
impede
flow
blood
oxygen
throughout
body
diminished
oxygen
delivery
tissues
organs
lead
complications
including
stroke
irreversible
organ
voxelotor
tablets
oxbryta
voxelotor
oral
therapy
patients
sickle
cell
disease
scd
oxbryta
works
increasing
hemoglobin
affinity
oxygen
since
oxygenated
sickle
hemoglobin
polymerize
gbt
believes
oxbryta
blocks
polymerization
resultant
sickling
destruction
red
blood
cells
primary
pathologies
faced
every
single
person
living
scd
potential
improve
hemolytic
anemia
oxygen
delivery
gbt
believes
oxbryta
potential
modify
course
scd
oxbryta
received
food
drug
administration
fda
accelerated
approval
treatment
scd
adults
children
years
age
condition
accelerated
approval
gbt
continue
study
oxbryta
study
confirmatory
study
using
transcranial
doppler
tcd
flow
velocity
assess
ability
therapy
decrease
stroke
risk
children
years
age
recognition
critical
need
new
scd
treatments
fda
granted
oxbryta
breakthrough
therapy
fast
track
orphan
drug
rare
pediatric
disease
designations
treatment
patients
scd
additionally
oxbryta
granted
priority
medicines
prime
designation
european
medicines
agency
ema
european
commission
ec
designated
oxbryta
orphan
medicinal
product
treatment
patients
scd
gbt
plans
seek
regulatory
approvals
expand
potential
use
oxbryta
united
states
treatment
scd
children
age
years
treat
hemolytic
anemia
scd
people
age
years
older
europe
important
safety
information
oxbryta
taken
patient
allergic
reaction
voxelotor
ingredients
oxbryta
see
end
patient
leaflet
list
ingredients
oxbryta
oxbryta
cause
serious
side
effects
including
serious
allergic
reactions
patients
tell
health
care
provider
get
emergency
medical
help
right
away
get
rash
hives
shortness
breath
swelling
face
patients
receiving
exchange
transfusions
talk
health
care
provider
possible
difficulties
interpretation
certain
blood
tests
taking
oxbryta
common
side
effects
oxbryta
include
headache
diarrhea
stomach
abdominal
pain
nausea
tiredness
rash
fever
possible
side
effects
oxbryta
taking
oxbryta
patients
tell
health
care
provider
medical
conditions
including
liver
problems
pregnant
plan
become
pregnant
known
oxbryta
harm
unborn
baby
breastfeeding
plan
breastfeed
known
oxbryta
pass
breastmilk
harm
baby
patients
breastfeed
treatment
oxbryta
least
two
weeks
last
dose
patients
tell
health
care
provider
medicines
take
including
prescription
medicines
vitamins
herbal
supplements
medicines
may
affect
oxbryta
works
oxbryta
may
also
affect
medicines
work
patients
advised
call
doctor
medical
advice
side
effects
side
effects
reported
fda
side
effects
also
reported
global
blood
therapeutics
full
prescribing
information
oxbryta
available
global
blood
therapeutics
global
blood
therapeutics
gbt
biopharmaceutical
company
dedicated
discovery
development
delivery
treatments
provide
hope
underserved
patient
communities
founded
gbt
delivering
goal
transform
treatment
care
sickle
cell
disease
scd
lifelong
devastating
inherited
blood
disorder
company
introduced
voxelotor
first
treatment
directly
inhibits
sickle
hemoglobin
polymerization
root
cause
red
blood
cell
sickling
scd
gbt
also
advancing
pipeline
program
scd
inclacumab
inhibitor
development
address
pain
crises
associated
disease
addition
gbt
drug
discovery
teams
working
new
targets
develop
next
generation
treatments
scd
learn
please
visit
follow
company
twitter
statements
certain
statements
press
release
within
meaning
private
securities
litigation
reform
act
including
statements
containing
words
anticipates
plans
believes
forecast
estimates
expects
intends
similar
expressions
statements
based
gbt
current
expectations
actual
results
could
differ
materially
statements
press
release
may
include
statements
historical
facts
considered
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
gbt
intends
statements
including
statements
regarding
gbt
priorities
dedication
focus
goals
vision
safety
efficacy
mechanism
action
oxbryta
product
characteristics
commercialization
delivery
availability
use
commercial
medical
potential
oxbryta
ongoing
planned
studies
oxbryta
related
protocols
activities
expectations
potential
expansion
approved
use
oxbryta
patients
potential
regulatory
approval
oxbryta
treat
patients
europe
raising
awareness
scd
europe
altering
treatment
course
care
scd
mitigating
related
complications
need
improve
quality
care
scd
patients
europe
potential
inclacumab
advancing
gbt
pipeline
working
new
targets
discovering
developing
delivering
treatments
covered
safe
harbor
provisions
statements
contained
section
securities
act
section
securities
exchange
act
gbt
makes
statement
purposes
complying
safe
harbor
provisions
statements
reflect
gbt
current
views
plans
intentions
expectations
strategies
prospects
based
information
currently
available
company
assumptions
company
made
gbt
give
assurance
plans
intentions
expectations
strategies
attained
achieved
furthermore
actual
results
may
differ
materially
described
statements
affected
variety
risks
factors
beyond
gbt
control
including
without
limitation
risks
uncertainties
relating
pandemic
including
extent
duration
impact
gbt
business
including
commercialization
activities
regulatory
efforts
research
development
corporate
development
activities
operating
results
depend
future
developments
highly
uncertain
accurately
predicted
ultimate
duration
pandemic
travel
restrictions
quarantines
social
distancing
business
closure
requirements
countries
effectiveness
actions
taken
globally
contain
treat
disease
risks
gbt
recently
established
commercialization
capabilities
may
able
successfully
commercialize
oxbryta
risks
associated
gbt
dependence
third
parties
development
manufacture
commercialization
activities
related
oxbryta
government
payor
actions
including
relating
reimbursement
pricing
risks
uncertainties
relating
competitive
products
changes
may
limit
demand
oxbryta
risks
regulatory
authorities
may
require
additional
studies
data
support
continued
commercialization
oxbryta
risks
adverse
events
may
observed
commercialization
clinical
development
data
results
may
meet
regulatory
requirements
otherwise
sufficient
development
regulatory
review
approval
compliance
funding
obligations
pharmakon
loan
timing
progress
gbt
syros
research
development
activities
collaboration
along
risks
set
forth
gbt
annual
report
form
fiscal
year
ended
december
gbt
recent
quarterly
report
form
filed
securities
exchange
commission
well
discussions
potential
risks
uncertainties
important
factors
gbt
subsequent
filings
securities
exchange
commission
except
required
law
gbt
assumes
obligation
update
publicly
statements
whether
result
new
information
future
events
otherwise
references
centers
disease
control
prevention
website
sickle
cell
disease
scd
https
ncbddd
sicklecell
accessed
june
european
medicines
agency
https
en
medicines
human
accessed
june
national
heart
lung
blood
institute
website
sickle
cell
disease
https
accessed
august
rees
dc
et
al
lancet
kato
gj
et
al
nat
rev
dis
primers
kato
gj
et
al
j
clin
invest
caboot
jb
et
al
paediatr
respir
rev
oxbryta
voxelotor
tablets
prescribing
information
south
san
francisco
calif
global
blood
therapeutics
november
contact
steven
immergut
gbt
media
